Latest Period
Q4 2025
Security Snapshot
Apimeds Pharmaceuticals US, Inc. - Common Stock (APUS) Institutional Ownership
CUSIP: 03771D102
13F Institutional Holders and Ownership History from Q2 2025 to Q4 2025
Institutions Reporting
7
Shares (Excl. Options)
395,700
Price
$1.64
Save this security research path
Keep this CUSIP in your research flow, then return after the next filing cycle to check what changed.
- Type / Class
- Equity / Common Stock
- Symbol
- APUS on NYSE
- Shares outstanding
- 12,584,892
- Price per share
- $1.41
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 395,700
- Total reported value
- $648,947
- % of total 13F portfolios
- 0%
- Share change
- -4,283
- Value change
- -$15,296
- Number of holders
- 7
- Price from insider filings
- $1.41
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- APUS - Apimeds Pharmaceuticals US, Inc. - Common Stock is tracked under CUSIP 03771D102.
- 7 institutions reported positions in Q4 2025.
- 2 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 8 to 7 between Q3 2025 and Q4 2025.
- Reported value moved from $711,810 to $648,947.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Official SEC Source
Backed by Form 13F
Ownership context comes from SEC Form 13F and, when available, Schedule 13D/13G filings.
See Original FilingInvestment Quick Answers
What is CUSIP 03771D102?
CUSIP 03771D102 identifies APUS - Apimeds Pharmaceuticals US, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Continue Investment Research
- Latest 13F filings for new institutional portfolio disclosures.
- Latest Schedule 13D/13G reports for activist and beneficial ownership updates.
- Latest 10-Q/10-K reports to cross-check issuer fundamentals.
- Recent insider transactions for management buying/selling context.
- SEC investors directory and top value investors for manager-level discovery.
- All institutional ownership pages to compare adjacent CUSIP pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 03771D102:
Significant Owners of Apimeds Pharmaceuticals US, Inc. - Common Stock (APUS) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Inscobee Inc. | 34% | 0% | $5,870,600 | 4,316,618 | 0% | Apimeds Inc. | 25 Mar 2026 | |
| Ayrton Capital LLC | 10% | $2,612,429 | 1,397,021 | Ayrton Capital LLC | 31 Dec 2025 |
As of 31 Dec 2025, 7 institutional investors reported holding 395,700 shares of Apimeds Pharmaceuticals US, Inc. - Common Stock (APUS). This represents 3.1% of the company’s total 12,584,892 outstanding shares.